Vyndaqel
AstraZeneca goes bigger in amyloidosis with Neurimmune deal
Phil Taylor
Alnylam Pharmaceuticals, AstraZeneca, ATTR amyloidosis, eplontersen, Neurimmune, NI006, Onpattro, Pfizer, Vyndaqel
0 Comment
X
AstraZeneca goes bigger in amyloidosis with Neurimmune deal
https://pharmaphorum.com/news/astrazeneca-goes-bigger-in-amyloidosis-with-neurimmune-deal/
NICE says ‘no’ to Pfizer’s Vyndaqel for rare heart condition
Richard Staines
cost-effectiveness, market access, NICE, Vyndaqel
0 Comment
X
NICE says ‘no’ to Pfizer’s Vyndaqel for rare heart condition
https://pharmaphorum.com/news/nice-says-no-to-pfizers-vyndaqel-for-rare-heart-condition/
Pfizer’s EU Vyndaqel okay ‘sets up $1.5bn sales next year’
Phil Taylor
ema, EU, Pfizer, rare disease, Vyndaqel
0 Comment
X
Pfizer’s EU Vyndaqel okay ‘sets up $1.5bn sales next year’
https://pharmaphorum.com/news/pfizers-eu-vyndaqel-okay-sets-up-1-5bn-sales-next-year/